Powder: -20°C for 3 years | In solvent: -80°C for 1 year
FPH1 (BRD-6125) 在体外能够提高人肝原代细胞的活性及数量,并促进 iPS 细胞向肝系分化。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
2 mg | ¥ 258 | 现货 | ||
5 mg | ¥ 463 | 现货 | ||
10 mg | ¥ 795 | 现货 | ||
25 mg | ¥ 1,590 | 现货 | ||
50 mg | ¥ 2,150 | 现货 | ||
100 mg | ¥ 3,230 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 571 | 现货 |
产品描述 | FPH1 (BRD-6125) (BRD-6125) can promote the expansion of iPS-derived hepatocytes. |
体外活性 | FPH1 在体外诱导肝细胞的功能性增殖,并导致更加明显的肝细胞形态学变化,包括多边形细胞形状、清晰可见的细胞核,以及肝细胞间更加突出的胆管结构。[1] |
激酶实验 | Cytochrome P450 Inhibition: Inhibition of human cytochrome P450 activities is determined in duplicate in pooled human hepatic microsomal fractions following current scientific and regulatory guidelines. Reaction conditions are linear with respect to incubation time and hepatic microsomal protein concentration. Substrates are present at concentrations equal to or less than their respective Km values determined under the same reaction conditions. Metabolite and/or substrate concentrations are determined using specific, internal standard controlled HPLC MS/MS assays. For reactions monitoring metabolite formation there is less than 20% consumption of substrate during the reaction. Unless otherwise noted microsomal fraction, diluted in potassium phosphate buffer, is preincubated with substrate and inhibitor for 5 min at 37 ℃ and the reaction initiated by the addition of an NADPH generating system followed by further incubation at 37 ℃ with shaking. Enzyme-selective positive control inhibitors are tested in parallel. At appropriate times aliquots of the mixture are removed and the reaction terminated by addition to a mixture of methanol and acetonitrile containing the respective internal standard. After centrifugation aliquots of the supernatant are subjected to HPLC-MS/MS analysis. |
别名 | BRD-6125 |
分子量 | 388.82 |
分子式 | C16H15ClF2N2O3S |
CAS No. | 708219-39-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 72 mg/mL (185.2 mM)
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.5719 mL | 12.8594 mL | 25.7188 mL | 64.2971 mL |
5 mM | 0.5144 mL | 2.5719 mL | 5.1438 mL | 12.8594 mL | |
10 mM | 0.2572 mL | 1.2859 mL | 2.5719 mL | 6.4297 mL | |
20 mM | 0.1286 mL | 0.643 mL | 1.2859 mL | 3.2149 mL | |
50 mM | 0.0514 mL | 0.2572 mL | 0.5144 mL | 1.2859 mL | |
100 mM | 0.0257 mL | 0.1286 mL | 0.2572 mL | 0.643 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
FPH1 708219-39-0 Others inhibit BRD 6125 FPH-1 FPH 1 BRD-6125 BRD6125 Inhibitor inhibitor